ReviewInternational journal of nanomedicine2018
Targeted nonviral gene therapy in prostate cancer.
Review in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- High RMI1 expression is associated with cancer cell progression and poor prognosis in prostate cancer.Oncology reports · 2026Article
- Camptothecin-Bearing PEGylated Polypropylenimine Dendriplexes for Prostate Cancer Gene Therapy: Impact of Microfluidic Processing on Physicochemical Properties and Transfection.Pharmaceutics · 2026Article
- Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (Journal of clinical medicine · 2026Review
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Intravenous Delivery of Angiopep-Functionalized Polypropylenimine Dendriplex Enhances Gene Expression in the Brain.International journal of nanomedicine · 2025Article
- Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.Molecular cancer · 2024Review
- Enhancing Transfection Efficacy in Glioma Cells: A Comparison of MicrofluidicInternational journal of nanomedicine · 2024Article
- Targeted RASSF1A expression inhibits proliferation of HER2‑positive breast cancer cellsExperimental and therapeutic medicine · 2023Article
- Report on Webinar Series Cell and Gene Therapy: From Concept to Clinical Use.Pharmaceutics · 2022Article
- The Comprehensive Analysis of Hub Gene ARRB2 in Prostate Cancer.Disease markers · 2022Article
- Development and Characterization of High Efficacy Cell-Penetrating Peptide via Modulation of the Histidine and Arginine Ratio for Gene Therapy.Materials (Basel, Switzerland) · 2021Article
- Review
- Lactoferrin-Bearing Gold Nanocages for Gene Delivery in Prostate Cancer Cells in vitro.International journal of nanomedicine · 2021Article
- In vivo gene delivery mediated by non-viral vectors for cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1.Frontiers in cell and developmental biology · 2020Article
- PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer.International journal of nanomedicine · 2020Article
- miR-1303 promotes the proliferation, migration and invasion of prostate cancer cells through regulating the Wnt/β-catenin pathway by targeting DKK3.Experimental and therapeutic medicine · 2019Article
- Biodegradable Polymers for Gene Delivery.Molecules (Basel, Switzerland) · 2019Review
- A Winning New Combination? Toward Clinical Application in Oncology.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second-most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal therapy, and radiotherapy, which commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate this problem, a wide range of nonviral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various nonviral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on recent therapeutic advances made so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.